Literature DB >> 21072344

The missing zinc: p53 misfolding and cancer.

Stewart N Loh1.   

Abstract

The p53 tumor suppressor is a transcription factor that contains a single zinc ion near its DNA binding interface. Zn(2+) is required for site-specific DNA binding and proper transcriptional activation. In addition to its functional significance, zinc plays a dominant role in determining whether p53 folds productively or misfolds. Insufficient zinc and excess zinc cause p53 to misfold by distinct mechanisms which both result in functional loss. The zinc-binding status of p53 in the cell is impacted significantly by the presence of tumorigenic mutations and by metal ion homeostasis. This review discusses mechanisms by which zinc modulates folding and misfolding of p53, how improper metal binding and release leads to loss of function and cancer, and how misfolding can be rescued by metallochaperones.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21072344     DOI: 10.1039/c003915b

Source DB:  PubMed          Journal:  Metallomics        ISSN: 1756-5901            Impact factor:   4.526


  42 in total

Review 1.  Zinc and zinc-containing biomolecules in childhood brain tumors.

Authors:  Jan Hrabeta; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Sona Krizkova; Vojtech Adam
Journal:  J Mol Med (Berl)       Date:  2016-09-16       Impact factor: 4.599

2.  Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain.

Authors:  Sara Calhoun; Valerie Daggett
Journal:  Biochemistry       Date:  2011-05-17       Impact factor: 3.162

3.  Synthetic metallochaperone ZMC1 rescues mutant p53 conformation by transporting zinc into cells as an ionophore.

Authors:  Adam R Blanden; Xin Yu; Aaron J Wolfe; John A Gilleran; David J Augeri; Ryan S O'Dell; Eric C Olson; S David Kimball; Thomas J Emge; Liviu Movileanu; Darren R Carpizo; Stewart N Loh
Journal:  Mol Pharmacol       Date:  2015-02-20       Impact factor: 4.436

Review 4.  Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer.

Authors:  Adam R Blanden; Xin Yu; Stewart N Loh; Arnold J Levine; Darren R Carpizo
Journal:  Drug Discov Today       Date:  2015-07-20       Impact factor: 7.851

Review 5.  Molecularly targeted therapies for p53-mutant cancers.

Authors:  Dekuang Zhao; William M Tahaney; Abhijit Mazumdar; Michelle I Savage; Powel H Brown
Journal:  Cell Mol Life Sci       Date:  2017-06-22       Impact factor: 9.261

Review 6.  Micronutrient imbalance and common phenotypes in neural tube defects.

Authors:  Anneke Dixie Kakebeen; Lee Niswander
Journal:  Genesis       Date:  2021-10-19       Impact factor: 2.487

Review 7.  Drugging the p53 pathway: understanding the route to clinical efficacy.

Authors:  Kian Hoe Khoo; Khoo Kian Hoe; Chandra S Verma; David P Lane
Journal:  Nat Rev Drug Discov       Date:  2014-03       Impact factor: 84.694

8.  Inhibition of aminoglycoside 6'-N-acetyltransferase type Ib by zinc: reversal of amikacin resistance in Acinetobacter baumannii and Escherichia coli by a zinc ionophore.

Authors:  David L Lin; Tung Tran; Jamal Y Alam; Steven R Herron; Maria Soledad Ramirez; Marcelo E Tolmasky
Journal:  Antimicrob Agents Chemother       Date:  2014-05-12       Impact factor: 5.191

9.  p53 reactivation: the link to zinc.

Authors:  Gabriella D'Orazi; David Givol
Journal:  Cell Cycle       Date:  2012-07-15       Impact factor: 4.534

10.  An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.

Authors:  Dennis Bromley; Matthias R Bauer; Alan R Fersht; Valerie Daggett
Journal:  Protein Eng Des Sel       Date:  2016-08-08       Impact factor: 1.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.